Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
NKTR Stock Chart & Stats
$37.64
-$0.04(-3.36%)
At close: 4:00 PM EST
$37.64
-$0.04(-3.36%)
Day’s Range― - ―
52-Week Range$6.49 - $66.92
Previous CloseN/A
Volume706.47K
Average Volume (3M)628.77K
Market Cap
$765.66M
Enterprise Value$765.28M
Total Cash (Recent Filing)$270.21M
Total Debt (Recent Filing)$91.92M
Price to Earnings (P/E)―
Beta4.23
Next Earnings
Mar 04, 2026EPS Estimate
-2.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding20,341,589
10 Day Avg. Volume714,435
30 Day Avg. Volume628,769
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.15
Price to Sales (P/S)1.94
P/FCF Ratio-1.08
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue12.22
Enterprise Value/Gross Profit14.01
Enterprise Value/Ebitda-8.84
Forecast
1Y Price Target
$103.88Price Target Upside175.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deepening Efficacy Over TimeClinical data indicate treatment responses deepen with continued dosing, suggesting rezpeg may avoid an early efficacy plateau and deliver improving benefit over time.
Phase 3 Design And Commercial PositioningManagement's Phase 3 plan to enroll both biologic-naive and biologic-experienced patients and pursue a less frequent maintenance regimen could support a broader label and improve payer and prescriber acceptance.
Safety And Tolerability DifferentiationRezpeg demonstrates a favorable safety and tolerability profile with primarily mild injection-site reactions and no signals of major adverse events, supporting potential positioning as a safer alternative to JAK inhibitors.
Bears Say
Competitive Adoption RiskUnderperformance relative to existing therapies could limit physician adoption and constrain market uptake even if regulatory approval is obtained.
Missed Statistical Significance On Key EndpointKey alopecia areata endpoints in the Phase 2 readout missed statistical significance, creating uncertainty about the therapy's efficacy versus placebo.
Post-hoc Patient Exclusions And Data IntegrityPost-hoc exclusion of patients by the CRO for eligibility violations raises concerns about data handling and could weaken confidence in the trial results.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $6.49 and its highest was $66.92 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $765.66M.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Mar 04, 2026 which is in 26 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$2.685 by $0.815.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.42.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 20,341,589 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.87 in its last earnings report, beating expectations of -$2.685. Following the earnings report the stock price went up 1.542%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$103.88 (175.98% Upside)
$103.88 (175.98% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 963.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $182.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.8%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.24%
12-Months-Change
Fundamentals
Return on Equity
-180.24%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong financial health, significant progress in clinical trials, and recognition for their scientific contributions. The challenges with existing treatments in alopecia areata were acknowledged but present an opportunity for REZPEG to fill a critical need.View all NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$103.88
▲(175.98% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
5.13% Insiders
9.50% Mutual Funds
34.52% Other Institutional Investors
44.42% Public Companies and Individual Investors